February 24, 2022 02:10 PM ESTUpdated February 25, 11:05 AM
Pharma

Ab­b­Vie slams the pen­sion door to new hires as Big Phar­ma hold­outs fi­nal­ly join the mi­gra­tion to 401Ks

Paul Schloesser

Associate Editor

When As­traZeneca’s US sub­sidiary an­nounced it would be ax­ing its $1.3 bil­lion pen­sion plan a few weeks ago, the sec­ond half of End­points News‘ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times